Copyright
©The Author(s) 2015.
World J Gastroenterol. Nov 7, 2015; 21(41): 11621-11635
Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11621
Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11621
Study | Total /eval pts | Performance Status, n | II-line treatment,doses (mg/m2) | TreatmentORR | Median TTP (mo) | MedianPFS(mo) | MedianOS(mo) | Toxicity,grade3-4 (%) | Ref. |
Irinotecan/ FU | 40/38 | ECOG 0/1/2 - 5/21/12 | Iri/FA/FU - 180/125/400 bolus + 1200 inf over 22 h d1/d1/d1 q14 | 29.0% | NR | 3.7 | 6.4 | A/N/FN/I/N-E/D/As - 13/26/5/16/13/8/16 | Assersohn et al[31], 2004 |
Irinotecan/ FU | 64/57 | ECOG 0/1/2 - 3/58/3 | Iri/FU/FA - 150/100/1000 d1/d1/d1, 2 over 24 h q14 | 21.0% | 2.5 | NR | 7.6 | N/T/D/E - 11/8/3/3 | Kim et al[32], 2005 |
Irinotecan/ FU | 51/48 | ECOG 0-1/2 - 35/16 | Iri/FA/FU - 180/200/400 bolus + 600 inf over 22 h d1/d1/d1 q14 | 18.0% | NR | 3.2 | 9.1 | A/N/FN/D/Nau/E - 14/17/1/6/6/4 | 1Seo et al[33], 2008 |
Irinotecan/ Cisplatin | 32/31 | ECOG 0/1/2 - 1/22/9 | Iri/P - 70/30 d1, 15/d1, 15 q28 | 15.6% | 3.7 | NR | 6.1 | A/N/T/E/D/M/Ano - 2.6/6/4.3/1.7/1.7/3.4/5.2 | Baek et al[34], 2005 |
Irinotecan/ Cisplatin | 87/70 | ECOG 0/1/2 - 29/53/5 | Iri/P - 70/80 d1, 15/d1 q28 | 28.6% | 4.3 | NR | 9.5 | A/L/N/FN/T/D/As/Nau - 28/34/40/10/8/6/5/2 | 1Takahari et al[35], 2010 |
Irinotecan/ Mitomycin C | 38/38 | KPS Median 80 (R 70-100%) | Iri/MMC - 150/8 d1, 15/d1 q28 | 32.0% | 4.0 | NR | 8.0 | A/L/N - 5/8/21 | Giuliani et al[36], 2005 |
Irinotecan/ Mitomycin C | 45 | ECOG 0/1 - 24/21 | Iri/MMC - 150/5 d1 q14 | 29.0% | NR | 4.1 | 10.1 | A/N/FN/D/I - 13/53/9/2/4 | Hamaguchi et al[37], 2011 |
Irinotecan/ Capecitabine | 48/46 | ECOG 0/1/2 - 10/32/6 | Iri/Cap - 100/1000 b.i.d d1, 8/d1-14 q21 | 27.1% | 4.1 | NR | 7.6 | N/FN/E/D/HFS - 8.7/4.3/4.3/17.4/4.3 | Sun et al[38], 2009 |
Irinotecan/ Cetuximab | 63/54 | ECOG 0/1 - 28/35 | Iri/Cet - 180/500 d1 q14 | 11.0% | NR | 2.8 | 6.1 | N/FN/D/F - 11/2/6/5 | Schønnemann et al[39], 2012 |
Irinotecan vs | 29 vs 30 | ECOG 0/1 - 27/2 vs 27/3 | Iri 150 d1 q14 | 17.2% vs 20.0% | NR | 2.2 vs 3 | 5.8 vs 6.7 | A/n/Leu/FN/Ano/As/D - 0/20/28/0/10/10/3 vs 10/13/37/3/13/3/7 | Sym et al[40], 2013 |
Irinotecan/ mFOLFIRI | Iri/mFOLFIRI 150 d1 + LV20 d1, 5-FU 2000 over 48 h | ||||||||
Paclitaxel/ Doxifluridine | 52/25 | ECOG R 0-2 | Dox/Ptx - 600 mg/70 d1-21/d7, 14, 21 q28 | 28.0% | NR | NR | 5.8 | L - 2 | Arai et al[41], 2007 |
Paclitaxel/ Doxifluridine | 33 | ECOG 0/1/2 - 21/14/0 | Dox/Ptx - 600 mg/70 d1-14/d1, 8 q21 | 18.2% | NR | 4.0 | 10.7 | A/L/N/D/FN/I/As/Neu - 17.1/11.4/22.9/2.9/ 2.9/2.9/2.9 | Takiuchi et al[42], 2008 |
Paclitaxel/ Carboplatin | 50/47 | ECOG 0-1/2 - 25/22 | Ptx/Carbo - 175/AUC 5 d1/d1 q21 | 27.7% | NR | NR | OS in PR/SD - 10.0/6.0 | N/T - 8.5/4.2 | Stathopoulos et al[43], 2002 |
Paclitaxel/ Cisplatin | 32/30 | ECOG 0-1/2 - 21/11 | Ptx/P - 145/60 d1 q21 | 25.0% | 2.9 | NR | 9.1 | N/E/Neu - 3/9/6 | Lee et al[44], 2007 |
Paclitaxel/ Capecitabine | 26/26 | ECOG 0/1/2 - 7/11/8 | Ptx/Cap - 175/825 b.i.d d1/d1-14 q21 | 34.6% | 4.5 | NR | 7.5 | A/N/T/HFS/Neu/Ar/E - 3.8/11.5/3.8/11.5/ 11.5/7.5/3.8 | Baize et al[45], 2009 |
Paclitaxel/ Capecitabine | 36/35 | KPS Median 80 (R 60-100%) | Ptx/Cap - 80/1000 b.i.d d1, d8/d1-14 q21 | 28.5% | NR | 5.0 | 11.1 | N/N-E/HFS - 11.1/5.6/5.6 | Zhang et al[46], 2013 |
Paclitaxel/ S-1 | 30 | ECOG 0-1/2 -23/7 | Ptx/S-1 - 120 d1 q14 /80, 100, 120 mg/d, if BSA < 1.25 m2, 1.26 m2-1.49 m2, ≥ 1.50 m2 b.i.d. d1-7 q14 | 33.3% | NR | 3.6 | 7.2 | A/Neu/T/Ano/Neu/D/F - 73.4/63.4/16.6/20/36.6/13.3/20 | Zheng et al[47], 2014 |
Docetaxel/ Cisplatin | 43/41 | ECOG 0/1/2 - 1/33/9 | Dtx/P - 60/60 d1/d1 q21 | 17.1% | NR | 2.2 | 5.8 | N/N-E/Neu/Neph - 29.3/12.2/4.9/2.3 | Park et al[48], 2004 |
Docetaxel/ Cisplatin | 30/30 | KPS 50-70/ 80-100% - 14/16 | Dtx/P - 60/60 d1/d1 q21 | 26.7% | 4.5 | NR | 5.6 | A/L/N/Nau - 3/27/27/3 | Kunisaki et al[49], 2005 |
Docetaxel/ Cisplatin | 32/32 | ECOG 0/1/2 - 8/16/8 | Dtx/P 70/70 d1/d1 q21 | 16.0% | 5.0 | NR | 6.0 | N/FN/T/D - 59/12/12/6 | Polyzos et al[50], 2006 |
Docetaxel/ Oxaliplatin | 38/37 | ECOG 0/1/2 - 19/12/7 | Dtx/Ox - 75/80 d1/d2 q21 | 10.5% | 4.0 | NR | 8.1 | N/As/Nau/Neu - 26.3/15.7/15.7/3 | Barone et al[51], 2007 |
Docetaxel/ Oxaliplatin | 48/46 | ECOG 0/1/2 - 11/29/8 | Dtx/Ox - 60/130 d1 q21 | 22.9% | 4.4 | NR | 7.2 | L/N/FN/T/N-E/D/Neu - 17.4/26/7/4.3/28.3/ 15/6.5 | Zhong et al[52], 2008 |
Docetaxel/ Epirubicin | 50/45 | ECOG 0/1/2 - 12/16/22 | Dtx/Epi - 75/60 d1/d1 q21 | 15.5% | 2.4 | NR | 5.0 | N/FN/T/N-E/S/D/Neu - 68/48/46/2/8/4/2 | Nguyen et al[53], 2006 |
Docetaxel/ Capecitabine | 28/25 | ECOG 0/1/2 - 2/19/7 | Dtx/Cap - 60/1000 b.i.d d1/d1-14 q21 | 29.0% | 4.0 | NR | 6.0 | A/N/As/D/HFS - 7/36/7/11/7 | Rosati et al[54], 2007 |
Docetaxel/ Etoposide | 32/32 | ECOG 0/1/2 - 6/20/6 | Dtx/Eto - 75/50 d1/d1-5 q21 | 9.4% | NR | 3.0 | 6.0 | N/FN/T/N-E/D/M - 29/19/3/15.6/9.4/6.2 | Yildiz et al[55], 2010 |
Docetaxel/ Cetuximab | 38/35 | ECOG 0/1/2 - 15/21/2 | Dtx/Cet - 30 d1, d15 q21/400 d1, then 250 d1 q7 | 6.0% | NR | 2.1 | 5.4 | I/FN/Ano/D/F - 11/3/16/11/29 | Tebbutt et al[56], 2013 |
Mitomycin/ S1 | 43/33 | ECOG 0/1/2 - 13/21/9 | MMC/S-1 - 7/40 b.i.d d1/d1-28 q42 | 21.0% | NR | 3.4 | 8.0 | A/N/T/D/N-E/As/S - 7/5/5/10/7/12/10 | Park et al[57], 2008 |
Mitomycin/ Capecitabine | 39 | ECOG 0/1/2/UNK - 6/25/5/3 | MMC/Cap - 10/1000 bid d1/d1-d14 q21 | 10.3% | NR | 2.8 | 5.6 | Leu/T/D/F/HFS/Neu - 5.4/10.8/5.4/8.1/5.4/8.1 | Miranda et al[58], 2014 |
Methotrexate/ FU | 56/55 | ECOG 0/1/2/3 - 12/30/12/2 | Mtx/FU/FA - 100 bolus/600 bolus (3 h after MTX)/10, every 6 h for 6 doses (24 h after MTX) q7 | 9.0% | NR | NR | 7.8 | A/L/N/T/N-E/D/S - 9.1/5.5/6.7/1.8/3.6/ 3.6/1.8 | Hamaguchi et al[59], 2008 |
Cisplatin/ FU | 58/53 | ECOG 0-1/2 - 20/33 | P/FU - 20/1000 over 20 h inf d1-5/d1-5 q28 | 11.3% | 1.8 | NR | 4.6 | A/N/T/N-E/D/M/Neu - 8/9/9/11/4/6/1 | Sencan et al[60], 2008 |
Oxaliplatin/ Sorafenib | 40 | ECOG 0/1/2 - 14/23/2 | Ox/Sor - 130 d1 q21/400 mg b.i.d daily | 2.8% | NR | 3.0 | 6.5 | N/T/As/D/Neu - 9.8/7.3/18/4.9/4.9 | Martin-Richard et al[61], 2013 |
- Citation: Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015; 21(41): 11621-11635
- URL: https://www.wjgnet.com/1007-9327/full/v21/i41/11621.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i41.11621